MaxCyte, Inc. Director/PCA transaction initial notification (0553X)

TIDMMXCT TIDMTTM

RNS Number : 0553X

MaxCyte, Inc.

16 December 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director/PCA transaction initial notification

Gaithersburg, Maryland - 16 December 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company announces that John Johnston, Non-Executive Director, has transferred 17,041 ordinary shares of 0.1 pence each in the Company (Ordinary Shares) to his wife, Karin Johnston, a person closely associated (PCA). The transfer took place on 14 December 2019.

Following the transaction, the number of shares in which John Johnston has an interest remains unchanged at 120,583 Ordinary Shares.

This announcement, including the notification below, is made in accordance with the requirements of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                                          John Johnston 
     ============================================  ============================================ 
 2    Reason for the notification 
     ========================================================================================== 
 a)   Position/status                               Non-Executive Director and PDMR 
     ============================================  ============================================ 
 b)   Initial notification/Amendment                Initial notification 
     ============================================  ============================================ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ========================================================================================== 
 a)   Name                                          MaxCyte, Inc. 
     ============================================  ============================================ 
 b)   LEI 
     ============================================  ============================================ 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ========================================================================================== 
 a)   Description of                                Ordinary shares 
       the financial 
       instrument, type 
       of instrument 
     ============================================  ============================================ 
 b)   Identification 
       Code 
     ============================================  ============================================ 
 c)   Nature of the                                 Transfer of Ordinary Shares to spouse/PCA 
       transaction 
     ============================================  ============================================ 
 d)   Price(s) and volume(s)                        Price(s)               Volume(s) 
     ============================================  ======================  ==================== 
 
 e)   Aggregated information                        N/A 
       - Aggregated volume                           17,041 
       - Price 
     ============================================  ============================================ 
 f)   Date of the transaction                       14 December 2019 
     ============================================  ============================================ 
 g)   Place of the transaction                      London Stock Exchange, AIM Market (XLON) 
     ============================================  ============================================ 
 

For further information, please contact:

 
 MaxCyte Inc. 
 Doug Doerfler, Chief Executive Officer 
  Ron Holtz, Chief Financial Officer        [phone] 
 
   Nominated Adviser and Joint Corporate 
   Broker 
   Panmure Gordon 
   Emma Earl 
   Freddy Crossley 
   Corporate Broking 
   James Stearns                              [phone] 
 Joint Corporate Broker 
  Numis Securities Limited 
  James Black 
  Duncan Monteith                             [phone] 
 
   Financial PR Adviser 
   Consilium Strategic Communications 
 Mary-Jane Elliott                          [phone] 
  Chris Welsh                                [e-mail] 
  Sukaina Virji 
 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEAXAKFADNFFF

(END) Dow Jones Newswires

December 16, 2019 12:25 ET (17:25 GMT)